Clinton Group’s Inovio Pharmaceuticals INO Stock Holding History

Clinton Group’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,974	Closed	-$330K	–	980
2016 Q2	$330K	Buy	+2,974	New	+$361K	0.01%	725

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Clinton Group's INO Position: Q3 2016 in Review

Clinton Group sold out of Inovio Pharmaceuticals (INO) in Q3 2016, closing a stake of 2,974 shares — an estimated $330K sold.

Clinton Group first reported a position in INO in Q2 2016 and held it in 1 quarter. The position peaked at $330K in Q2 2016. 125 funds tracked by Wall St. Rank hold INO as of Q3 2016.

Clinton Group reported no remaining Inovio Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Clinton Group sold 2,974 Inovio Pharmaceuticals shares in Q3 2016, an estimated $330K.
Clinton Group first reported a position in Inovio Pharmaceuticals in Q2 2016 and held it in 1 quarter.
Clinton Group's Inovio Pharmaceuticals position peaked at $330K in Q2 2016.
125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2016.

Based on Clinton Group's 13F filing for Q3 2016, filed 14 Nov 2016.